Neurocognitive Effects of Antiretroviral Initiation Among People Living With HIV in Rural Uganda

J Acquir Immune Defic Syndr. 2020 Aug 15;84(5):534-542. doi: 10.1097/QAI.0000000000002385.

Abstract

Background: HIV-associated neurocognitive disorders remain prevalent despite effective antiretroviral therapy (ART), but there are limited longitudinal data on people living with HIV (PLWH) in sub-Saharan Africa. We examined neuropsychological (NP) performance in PLWH in a longitudinal study in Uganda.

Methods: Participants enrolled through the Rakai Community Cohort Study (400 ART-naive PLWH and 400 matched HIV-negative persons) were administered NP assessments. In 2017, PLWH who had initiated ART underwent a 2-year follow-up assessment. Demographically adjusted Z-scores for each NP test were established using data from the HIV- controls. Multivariable linear and logistic regressions were conducted to examine group differences in NP performance. Mixed-effects regressions were conducted to examine ART-related changes in NP outcomes.

Results: Of 333 PLWH who returned for their 2-year follow-up visit, 312 (94%) had initiated ART. Those on ART had a mean age of 35.6 years (SD ± 8.5 years) and mean education of 5.4 years (SD ± 3.3 years); 49% were women. ART-associated NP improvements occurred in verbal learning and memory (P's < 0.05), motor (P's < 0.01), and some measures of processing speed (P = 0.002), whereas there were declines in attention/working memory (P's < 0.001) and semantic fluency (P < 0.001). Pre-ART CD4 count and efavirenz use were associated with a more impaired change in NP performance.

Conclusions: PLWH in this resource-limited setting showed improved neurocognitive performance on most NP tests after ART initiation. However, the declines in attention/working memory and fluency performance, as well as relationship to efavirenz, warrant further study.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alkynes / adverse effects
  • Alkynes / therapeutic use
  • Anti-HIV Agents / adverse effects*
  • Anti-HIV Agents / therapeutic use*
  • Benzoxazines / adverse effects
  • Benzoxazines / therapeutic use
  • Cognition
  • Cohort Studies
  • Cyclopropanes / adverse effects
  • Cyclopropanes / therapeutic use
  • Female
  • HIV Infections / complications*
  • HIV Infections / epidemiology*
  • HIV-1*
  • Humans
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Neurocognitive Disorders / chemically induced*
  • Neuropsychological Tests
  • Rural Population
  • Uganda / epidemiology

Substances

  • Alkynes
  • Anti-HIV Agents
  • Benzoxazines
  • Cyclopropanes
  • efavirenz